Sun Pharma flags hypertension drug shortage due to supply constraint

The company said it does not source the active pharmaceutical ingredients (API) of the drug from China, adding that supply of some other APIs was impacted by the coronavirus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/39fI1Oz
via IFTTT